HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome
<h2>Purpose</h2> <p>Apocrine carcinoma of the breast (APO) expresses HER2 in 30–50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort.</p> <h2>Methods</h2> <p>We used the SEER database to exp...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513567932284928 |
|---|---|
| author | Faruk Skenderi (6616190) |
| author2 | Mohamad Alhoda Mohamad Alahmad (14150928) Emin Tahirovic (4812702) Yaman M. Alahmad (14150931) Zoran Gatalica (3353003) Semir Vranic (3353012) |
| author2_role | author author author author author |
| author_facet | Faruk Skenderi (6616190) Mohamad Alhoda Mohamad Alahmad (14150928) Emin Tahirovic (4812702) Yaman M. Alahmad (14150931) Zoran Gatalica (3353003) Semir Vranic (3353012) |
| author_role | author |
| dc.creator.none.fl_str_mv | Faruk Skenderi (6616190) Mohamad Alhoda Mohamad Alahmad (14150928) Emin Tahirovic (4812702) Yaman M. Alahmad (14150931) Zoran Gatalica (3353003) Semir Vranic (3353012) |
| dc.date.none.fl_str_mv | 2022-11-22T21:12:56Z |
| dc.identifier.none.fl_str_mv | 10.1007/s10549-022-06578-4 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/HER2-positive_apocrine_carcinoma_of_the_breast_a_population-based_analysis_of_treatment_and_outcome/21597192 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Oncology and carcinogenesis Cancer Research Oncology |
| dc.title.none.fl_str_mv | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h2>Purpose</h2> <p>Apocrine carcinoma of the breast (APO) expresses HER2 in 30–50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort.</p> <h2>Methods</h2> <p>We used the SEER database to explore the cohorts. Univariate and multivariate analyses were used to assess the survival. Based on ER and PR [steroid receptors/SR/] and HER2 status, we divided the cohorts to match the intrinsic molecular subtypes for comparisons.</p> <h2>Results</h2> <p>We retrieved 259 cases of HER2+/APO. Most HER2+/APO were SR negative (65%). HER2+/APO were more prevalent in the 80+ age group (24.7% vs. 15.7%, p < 0.001). HER2+/SR−/APO had a significantly lower histological grade than the HER2+/SR−/NST (p < 0.001). Breast cancer-related deaths were more prevalent in HER2+/NST (7.8% vs. 3.9%, p = 0.019). This was particularly evident between SR− subgroups (10.4% in HER2+/SR−/NST vs. 4.2% in HER2+/SR−/APO, p = 0.008) and was reaffirmed in breast cancer-specific survival in univariate analysis (p = 0.03). Other than race and SR status, HER2+/APO subgroups did not differ in clinicopathological parameters.</p> <h2>Conclusions</h2> <p>Our study confirms the rarity of the APO and reveals that SR status in APO does not affect these patients' prognosis. HER2+/APO tumors tend to have a less aggressive phenotype and a more favorable outcome despite a markedly lower ER/PR positivity.</p><h2>Other Information</h2> <p> Published in: Breast Cancer Research and Treatment<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s10549-022-06578-4" target="_blank">http://dx.doi.org/10.1007/s10549-022-06578-4</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0344962e6356f9befa680205a4181186 |
| identifier_str_mv | 10.1007/s10549-022-06578-4 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21597192 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcomeFaruk Skenderi (6616190)Mohamad Alhoda Mohamad Alahmad (14150928)Emin Tahirovic (4812702)Yaman M. Alahmad (14150931)Zoran Gatalica (3353003)Semir Vranic (3353012)Oncology and carcinogenesisCancer ResearchOncology<h2>Purpose</h2> <p>Apocrine carcinoma of the breast (APO) expresses HER2 in 30–50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort.</p> <h2>Methods</h2> <p>We used the SEER database to explore the cohorts. Univariate and multivariate analyses were used to assess the survival. Based on ER and PR [steroid receptors/SR/] and HER2 status, we divided the cohorts to match the intrinsic molecular subtypes for comparisons.</p> <h2>Results</h2> <p>We retrieved 259 cases of HER2+/APO. Most HER2+/APO were SR negative (65%). HER2+/APO were more prevalent in the 80+ age group (24.7% vs. 15.7%, p < 0.001). HER2+/SR−/APO had a significantly lower histological grade than the HER2+/SR−/NST (p < 0.001). Breast cancer-related deaths were more prevalent in HER2+/NST (7.8% vs. 3.9%, p = 0.019). This was particularly evident between SR− subgroups (10.4% in HER2+/SR−/NST vs. 4.2% in HER2+/SR−/APO, p = 0.008) and was reaffirmed in breast cancer-specific survival in univariate analysis (p = 0.03). Other than race and SR status, HER2+/APO subgroups did not differ in clinicopathological parameters.</p> <h2>Conclusions</h2> <p>Our study confirms the rarity of the APO and reveals that SR status in APO does not affect these patients' prognosis. HER2+/APO tumors tend to have a less aggressive phenotype and a more favorable outcome despite a markedly lower ER/PR positivity.</p><h2>Other Information</h2> <p> Published in: Breast Cancer Research and Treatment<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s10549-022-06578-4" target="_blank">http://dx.doi.org/10.1007/s10549-022-06578-4</a></p>2022-11-22T21:12:56ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s10549-022-06578-4https://figshare.com/articles/journal_contribution/HER2-positive_apocrine_carcinoma_of_the_breast_a_population-based_analysis_of_treatment_and_outcome/21597192CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215971922022-11-22T21:12:56Z |
| spellingShingle | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome Faruk Skenderi (6616190) Oncology and carcinogenesis Cancer Research Oncology |
| status_str | publishedVersion |
| title | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| title_full | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| title_fullStr | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| title_full_unstemmed | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| title_short | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| title_sort | HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome |
| topic | Oncology and carcinogenesis Cancer Research Oncology |